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Abstract
Attenuated Listeria monocytogenes (Lmat-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here
we show that in vitro Lmat-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells,
irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that,
when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lmat-LLO causes a strong decrease in
the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we
confirm that the anti-melanoma activity exerted in vivo by Lmat-LLO depends also on its ability to potentiate the immune
response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based
immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft
models.
Introduction
Melanoma is the most aggressive form of skin cancer and
remains a therapeutic challenge, especially when it reaches
the metastatic stage [1]. Since one of the reasons behind
aggressiveness resides in the marked ability displayed by
melanoma cells to evade immune recognition, over the
years many different therapeutic strategies have aimed at
potentiating the immune response of the organism against
the tumor. In particular, antibodies that unleash the full
potential of helper and killer T-lymphocytes have already
become a standard of care for metastatic melanoma patients
[2], while the enhanced recognition of cancer neo-antigens
holds great promise [3–5].
Spurred by these successful applications of systemic
immunotherapy, we have decided to assess the antitumoral
effects elicited by an attenuated and non-pathogenic version
of Listeria monocytogenes (Lmat). Among the micro-
organisms exploited as anticancer vaccines, Lmat was
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chosen in light of the strong and multifaceted immune
response that it triggers [6, 7], of its selective tropism for
cancer cells [8], as well as of its tractability and versatility
as drug delivery platform [9].
Here we show that the Lmat-LLO strain [9] very effi-
ciently kills a broad spectrum of melanoma cells in culture
and, when injected in the therapeutic setting in a genetically
engineered mouse model (GEMM) of melanoma [10], it
greatly impairs the growth and metastatic burden of mela-
noma tumors.
Results
The ability of Lmat-LLO [9] (for a description of listeria
strains used in this article, please refer to Supplementary
Fig. 1) to enter and replicate inside melanoma cells in
culture was suggested by the immunofluorescent staining of
intracellular clusters of bacteria (Fig. 1a) and was confirmed
by transmission electron microscopy, since we captured
dividing bacteria (Fig. 1b, Supplementary Fig. 2). Con-
sistently, we detected an increase in Lmat-LLO infection
rate over time (Fig. 1c). We also detected an increase in the
number of listeria-positive melanoma cells, which indicates
that Lmat-LLO is capable of spreading from cell to cell
(Fig. 1d, Supplementary Fig. 2e). We then investigated
whether Lmat-LLO infection results in cell mortality.
Treating infected cells with CellROX reagent, we found that
listeria causes the production of intracellular reactive oxy-
gen species (ROS, Fig. 1e) [11]. This indeed results in
apoptotic cell death (Fig. 1f, Supplementary Fig. 3), hence
in a dramatic decrease in cell viability (Fig. 1g). Critically,
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none of the above-mentioned biological effects (replication
inside melanoma cells (Fig. 1c), spreading across cells
(Supplementary Fig. 4), ROS production (Fig. 1e) and cell
killing (Fig. 1g)) was observed when we used the Lm(ct)
strain, which is impaired in the expression of the bacterial
protein LLO (Supplementary Fig. 1c). The different beha-
vior displayed by Lmat-LLO and Lm(ct) attests that the
biological effects observed with Lmat-LLO are con-
sequences of the bacterial life cycle rather than of a general
toxicity phenomenon.
Next, we aimed at assessing whether the ability of Lmat-
LLO to kill melanoma cells is broad-spectrum. Indeed, we
obtained similar kill rates in cell lines of different stage
(primary and metastatic) and of different BRAF, NRAS,
and NF1 mutational status (Supplementary Fig. 5). Inter-
estingly, we also found that Lmat-LLO is effective at killing
melanoma cells that are particularly refractory to treatment,
such as those that display acquired resistance to vemur-
afenib due to different molecular mechanisms (Fig. 1h) [12]
or those that are characterized by a higher degree of stem-
ness (CD166-positive [13] SK-Mel-5 cells (Fig. 1i),
CD271-positive [14] SK-Mel-2 and SK-Mel-28 cells (Fig.
1j-k, Supplementary Fig. 6).
Prompted by the strong effects observed in vitro, we
moved on to the assessment of the antimelanoma activity
exerted by Lmat-LLO in vivo. To this end, we exploited the
tissue-specific and inducible GEMM of metastatic mela-
noma developed by Dankort and colleagues [10] (Supple-
mentary Fig. 7). In this model, upon skin painting with 4-
hydroxitamoxifen (4-HT), Pten is loxed out (Supplementary
Fig. 8a) and Braf acquires the V600E mutation, so that
primary melanomas develop on site within few weeks
(Supplementary Fig. 8b). These tumors are highly pig-
mented (i.e. the neoplastic cells are melanin rich), and
heavily vascularized (Supplementary Fig. 8c-h). Further-
more, their growth is very fast—mice require euthanasia
within 6–7 weeks after tumor induction—and metastasize
rapidly to regional lymph nodes (LNs) and to the lungs
(Supplementary Fig. 9-10).
In order to test the efficacy of Lmat-LLO in a therapeutic
setting, we painted the back of 6 week-old mice with 4-HT
and started Lmat-LLO injections 4 weeks later, when the
primary tumor reached 50–100 mm3. One injection of high
dose Lmat-LLO (107 CFU) in the tumor area was followed
by 14 intraperitoneal (IP) injections of a lower Lmat-LLO
dose (105 or 106 CFU), one per day (Supplementary Fig.
11). The single intratumoral injection of a high dose of
listeria favors the accumulation of the bacterium in the
tumor microenvironment, while the serial injection of low
doses stimulate the immune system to react against the
bacterium itself [15]. The maximum dose of Lmat-LLO to
be injected IP (106 CFU) was chosen on the basis of IC50
calculation and absence of toxic side effects (Supplemen-
tary Fig. 12-13).
Lmat-LLO treatment causes a conspicuous decrease in both
the volume and the weight of primary tumors (Fig. 2a–c), so
that the normal tissue, where the CRE-mediated deletion of
Pten has not occurred, becomes more represented (Fig. 2d,
left). Consistently with the results obtained in vitro, the
impairment in tumor growth caused by Lmat-LLO is asso-
ciated with an increase in the number of apoptotic Cleaved
Caspase 3-positive cells (Fig. 2e). However, we also
detected an increase in the levels of IL-2, a cytokine that
promotes the differentiation of T cells (Fig. 2d, right) [16],
as well as in the number of CD3+ T-lymphocytes recruited
on site (Fig. 2f). Specifically, we detected a more pro-
nounced infiltration of the CD4+ (Supplementary Fig. 14)
Fig. 1 Lmat-LLO infects and kills melanoma cells. a–c Lmat-LLO is
able to replicate inside melanoma cells, as determined using immu-
nofluorescence (a), electron microscopy (b), and infection rate (c). In a
501 Mel cells were infected with MOI 3000 of Lmat-LLO for 3 h (left
panel) or 6 h (right panel). Lmat-LLO is stained in red using anti-
Listeria antibody, the F-actin of tumour cells is stained in green using
fluorescent Phallotoxin and the nuclei are stained in blue using DAPI.
The red clusters indicate that Lmat-LLO is able to replicate in the
cytoplasm of melanoma cells. Original magnification: 63×. In b an
example of listeria in division is captured using transmission electron
microscopy. The black arrow indicates the septum that divides
daughter cells (see Supplementary Fig. 2; scale bar: 500 nm). In c 501
Mel cells were infected with MOI 200 of Lmat-LLO. The increased
infection rate when 3 h and 6 h are compared confirms that Lmat-LLO
is able to replicate inside melanoma cells. Lm(ct), which lacks LLO
expression, is used as negative control. d Lmat-LLO can spread across
melanoma cells. 501 Mel cells were infected with MOI 200 of Lmat-
LLO for 3 h or 6 h. Intracellular Lmat-LLO levels were evaluated using
the anti-Listeria antibody. The increasing number of fluorescent cells
indicates that Lmat-LLO is able to spread from cell to cell. Uninfected
501 Mel cells are used as control (CT). e Infection of 501 Mel cells
with Lmat-LLO but not with Lm(ct) (MOI 200 for 6 h) causes ROS
production. f As a consequence of ROS production, an increase in
AnnexinV-positive apoptotic cells is observed. g Kill rate of Lmat-
LLO in 501 Mel cells. Alive and dead cells were counted by trypan
blue staining after 24 h of exposure to Lmat-LLO or Lm(ct) (MOI 300
and 3000). Representative pictures of CT, Lmat-LLO MOI 3000 and
Lm(ct) MOI 3000 are reported in the panels on the right. h Lmat-LLO
is effective at killing melanoma cells that show acquired resistance to
vemurafenib. Kill rate in parental 501 Mel, A375 and SK-Mel-28
melanoma cells, as well as in their vemurafenib-resistant derivatives
are reported. 501 Mel P1 resistant population and A375 C2 resistant
clone are characterized by the expression of BRAFV600E Δ[3-10]
splicing variant; in the A375 P2 resistant population, there is the
KRAS K117N mutation; SK-Mel-28 C1 resistant clone is character-
ized by the overexpression of EGFR and PDGFRbeta [12]. Alive and
dead cells were counted by trypan blue staining after 24 h of exposure
to Lmat-LLO at MOI 3000. i–k Lmat-LLO is effective at killing mel-
anoma cells with different degree of stemness. i Kill rate on unsorted
(pop), CD166 pos. and CD166 neg. SK-Mel-5 cells. j Kill rate on
unsorted (pop), CD271 pos. and CD271 neg. SK-Mel-2 cells. k Kill
rate on unsorted (pop), CD271 pos. and CD271 neg. SK-Mel-28 cells.
Alive and dead cells were counted by trypan blue staining after 24 h of
exposure to Lmat-LLO at MOI 3000. The graphs represent the mean ±
SEM of three independent experiments. *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001
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and the CD8+ (Fig. 2g) subpopulations, which are
responsible for cell-mediated and cytotoxic immunity
against listeria, respectively [7, 15, 17]. These results
confirm that in vivo Lmat-LLO potentiates the response
of the immune system against the tumor and, therefore, that
its antitumoral effects are at least in part non-cell autono-
mous [18].
We also assessed the ability of Lmat-LLO treatment to
impair the metastatic burden. Indeed, the measurements
obtained by ultrasound imaging indicate a decrease in the
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volume of regional LN (Fig. 2h, i and Supplementary
Fig. 15), which, according to visual inspection, correlates
with a decrease in melanin/melanoma deposits (Fig. 2j).
Consistently, we observed a decrease in the number of
metastatic nodules in the lungs (Supplementary Fig. 16).
Lmat-LLO treatment was not accompanied by overall
toxicity—it didn’t cause weight loss or liver lesions (Sup-
plementary Fig. 17)—and was characterized by selective
accumulation of bacteria at the anatomic sites of tumor
growth, confirming the renowned tropism of listeria for
cancer cells (Supplementary Fig. 18).
Discussion
The data we obtained in vitro attest the ability of Lmat-LLO
to kill a wide variety of melanoma cells. Therefore, they
suggest that Lmat-LLO treatment could overcome one of the
most challenging features displayed by melanoma tumors,
namely their high degree of heterogeneity [19].
Even more importantly, the data obtained in Braf/Pten
mice reveal for the first time that the activity of Lmat-LLO
is strong enough to be observed in spite of the fact that
the melanoma tumors, which form in a GEMM, are much
more heterogeneous than those that form in the xenograft
models used thus far [20]. Therefore, they offer the
rationale for testing new first-line treatment strategies that
revolve around Lmat-LLO and for doing so in a pre-
clinical setting that resembles human melanoma more
closely, hence is endowed with higher translational
relevance.
Considering its high versatility as a drug carrier, we
suggest that Lmat-LLO could be engineered to express
melanoma-associated antigens [21], so that the immune
system of the body is boosted even further, or conjugated
with a BRAF or a MEK inhibitor, providing an alternative
way to assess the combined effects of immunotherapy and
targeted therapy [22].
In light of the results we obtained in vitro, it should be
considered that injections of Lmat-LLO might be effective
also as a second-line treatment, on Braf/Pten mice that have
become resistant to BRAF [23] or MEK [10] inhibitors.
Finally, Braf/Pten mice can be used to evaluate if the
effects of Lmat-LLO are durable in time and if the tumors
that eventually start growing again remain sensitive to a re-
challenge [20]. Moreover, if mice with the Tyr::CreER+,
BrafCA/+, Pten+/lox genotype instead of the Tyr::CreER
+, BrafCA/+, Ptenlox/lox genotype are used for the
induction, primary tumors grow more slowly and morbidity
becomes related to metastases [24]. Therefore, a more
thorough assessment of the effects of Lmat-LLO on meta-
static sites can be obtained.
Materials and methods
Strains of Listeria monocytogenes
The characteristics of the strains of Listeria monocytogenes
used in this work (Lmat-LLO and Lm(ct)) are described in
Supplementary Fig. 1.
Fig. 2 Lmat-LLO inhibits the growth of primary melanoma tumors and
their metastatization to lymph nodes. a–c Lmat-LLO inhibits the
growth of primary melanoma tumors. a Representative pictures of
primary tumors (red line) developed by mice treated with saline
solution (NaCl) or the indicated doses of Lmat-LLO (one injection of
107 CFU in the tumor area was followed by one IP injection per day of
105 or 106 CFU for 14 days). For each experimental group, pictures
were taken at three time points (before treatment, after 1 week of
treatment and after 2 weeks of treatment). b, c Volume (b) and weight
(c) of primary tumors. The number of primary tumors (mice) analyzed
are: 12 (volume) and 13 (weight) for the NaCl group, 7 (volume) and 8
(weight) for the Lmat-LLO 107–105 group and 12 (volume and weight)
for the Lmat-LLO 107–106.group. d Expression levels of undeleted
Pten mRNA and IL-2 mRNA. Total RNA extracted from paraffin
embedded primary tumor samples was analyzed by qRT-PCR. Left:
Undeleted Pten mRNA levels were measured using a forward primer
located on exon 3 and a reverse located on exon 4–5, as reported in
[26]. The higher levels of undeleted Pten mRNA detected in mice
treated with Lmat-LLO compared to control mice are consistent with
the smaller size of primary tumors. Right: The higher levels of IL-2
mRNA detected in Lmat-LLO treated mice compared to control mice
provide a molecular confirmation of the induction of the immune
system by the vaccine. e Infection of tumor cells with Lmat-LLO
causes a significant increase in apoptotic cell death, as indicated by
Cleaved Caspase-3 immunostaining. The number of primary tumors
(mice) analyzed is five for each experimental group. Original magni-
fication: 40× (scale bar: 25 μm). f, g Infection of tumor cells with Lmat-
LLO causes a significant increase in T-lymphocytes infiltration, as
indicated by immunostaining of CD3+ (f) and CD8+ (g) cells. The
number of primary tumors (mice) analyzed is five for each experi-
mental group. Original magnification: 40× (scale bar: 20 μm). In b–g
the mean ± SEM is reported. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. h, i Lmat-LLO inhibits melanoma metastatization to
lymph nodes. h Volume of inguinal lymph nodes in mice treated with
saline solution (NaCl) or the indicated doses of Lmat-LLO, as mea-
sured by ultrasound imaging. The volume of right and left inguinal
lymph nodes was measured at three time points (before treatment, after
1 week and after 2 weeks of treatment). The total number of lymph
nodes (mice) analyzed was eight (four) for each experimental group. In
the graph, individual measurements are reported, as well as a line
connecting mean values. **p < 0.01. i 3D ultra high-frequency ultra-
sound reconstruction of a representative inguinal lymph node per
experimental group (with surface rendering and volume measurement
reported as picture in picture). The upper images were acquired before
treatment, while the lower images were acquired after 2 weeks of
treatment. j Melanin content of axillary, brachial, and inguinal lymph
nodes in mice treated with saline solution (NaCl) or the indicated
doses of Lmat-LLO. The total number of lymph nodes (mice) analyzed
was the following: 59 (13) for the NaCl group, 44 (8) for the Lmat-
LLO 107–105 group, 59 (12) for the Lmat-LLO 107–106 group. Black,
high melanin content; white, no or low melanin content. *p < 0.05,
**p < 0.01
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To obtain Lmat-LLO, the XFL-7 strain was electro-
porated with pGG-34 plasmid as reported in [25].
Analogously, to obtain Lm(ct), the XFL-7 strain was
electroporated with the pGG-34-OVA214-386 plasmid. Both
strains were subsequently grown in BHI medium with 34
μg/ml chloramphenicol at 37 °C.
Mice strain
B6.Cg-Braftm1Mmcm Ptentm1Hwu Tg(Tyr-cre/ERT2)13Bos/
BosJ mice were purchased from the Jackson Laboratory
(013590). For in vivo experiments, Tyr::CreER+ (hetero-
zygous for CreER), BrafCA/+ (heterozygous for
BrafV600E), and Ptenlox/lox (homozygous for Pten loss)
mice were used, as described in Supplementary Fig. 11.
Mice were treated in compliance with the animal protocol
#754/2015-PR, initially approved by the Italian Ministry of
Heath on July 27th 2015 and then amended on September
12th 2018.
Statistical analyses
Statistical analyses were performed using unpaired and two-
tailed Student t-test or Chi-square test, as needed. Values of
p < 0.05 were considered statistically significant (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001).
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